AI Transparency Report
Cure Duchenne demonstrates a strong commitment to its mission, as evidenced by its consistent program spending. While the organization has experienced fluctuations in revenue, notably a significant spike in 2019 to over $27 million, its expenses have shown a steady increase, indicating growing operational capacity. The organization's assets have also grown substantially over the years, from $6.7 million in 2018 to over $27 million in 2023, suggesting sound financial management and accumulation of resources to support its long-term goals. The consistent reporting of 0% officer compensation across all available filings is a significant indicator of transparency and a focus on directing funds towards the mission rather than executive salaries.
However, recent filings show expenses exceeding revenue, with 2023 revenue at $7,357,938 against expenses of $10,247,154, and similar trends in 2022 and 2021. This trend, if sustained, could impact long-term financial stability, although current asset levels appear robust enough to absorb these short-term deficits. The organization's NTEE code H50 (Diseases, Disorders, Medical Disciplines) aligns well with its name, Cure Duchenne, indicating a clear programmatic focus. Overall, Cure Duchenne appears to be a financially healthy organization with a strong mission focus and excellent transparency regarding executive compensation.